The European Medicines Agency just approved a new Moderna mRNA flu vaccine—after clinical data demonstrated strong protection for older adults. In the United States, the same technology is facing a political blockade.
The FDA recently refused to review an mRNA flu vaccine application—despite a 40,000-person clinical trial showing it outperformed standard flu shots in older adults. The agency later reversed course, but the damage was done:
